Watson Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Watson Pharmaceuticals's estimated annual revenue is currently $122M per year.(i)
  • Watson Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Watson Pharmaceuticals has 607 Employees.(i)
  • Watson Pharmaceuticals grew their employee count by -3% last year.

Watson Pharmaceuticals's People

NameTitleEmail/Phone
1
Senior ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$53.7M26716%N/AN/A
#2
$53.1M26421%N/AN/A
#3
$69.1M34426%N/AN/A
#4
$22.1M110-10%N/AN/A
#5
$151.8M75511%N/AN/A
#6
$63.9M31813%N/AN/A
#7
$29.9M14913%N/AN/A
#8
$1.7M17-6%$114.3MN/A
#9
$6.8M34-6%N/AN/A
#10
$12.5M62-9%N/AN/A
Add Company

What Is Watson Pharmaceuticals?

Watson Pharmaceuticals, Inc. (NYSE-WPI) is a global specialty pharmaceutical company with approximately $3 billion in revenues, a broad product line and operations in well-established and emerging markets.

keywords:N/A

N/A

Total Funding

607

Number of Employees

$122M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Watson Pharmaceuticals News

2022-04-19 - Parties feel time crunch in opioid trial as testimony shows opioid ...

Attorneys representing the defendants — Teva Pharmaceutical Industries LLC and a ... Leitch discussed Watson's purchase of the drug Kadian,...

2022-04-17 - Attorney general announces $99 million settlement with Janssen ...

The Allergan defendants include Allergan Finance, LLC, formerly known as Actavis, Inc., fka Watson Pharmaceuticals, Inc.; Allergan Sales LLC...

2022-04-17 - West Virginia AG Morrisey announces $99M settlement with Janssen Pharmaceuticals

The Attorney General alleged Janssen Pharmaceuticals Inc., ... LLC; Actavis Pharma Inc., fka Watson Pharma Inc.; Actavis South Atlantic LLC;...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$190.4M6070%N/A
#2
$7.5M60717%N/A
#3
$248.9M60712%N/A
#4
$250.4M6077%N/A
#5
$76M6087%N/A